GleamWall
中文EN

PALI PALISADE BIO, INC.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1357459 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-289.2%
TTM EPS YoY144.4%
Revenue 3-yr CAGR-98.7%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-9,625,400,000.0%
Net margin-8,739,200,000.0%
FCF margin—
EBITDA margin-9,625,400,000.0%

Returns

ROE-75.6%
ROA-69.6%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets5.1%
Debt / equity0.00x
Current ratio20.16x
Interest coverage-16,042.33x

Cash quality & payout

Operating cash flow / net income0.60x
Accruals ratio-27.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$0$0$0$0$0$0$0
R&D expense$12.00M$6.00M$6.00M$6.17M$1.39M$1.68M$950,000$0
SG&A expense$5.12M$4.80M$4.35M$3.81M$1.53M$1.17M$1.36M$1.30M
Operating income-$15.70M-$11.70M-$10.75M-$9.98M-$2.92M-$2.84M-$2.31M-$3.38M
Interest expense$0$0$1,000$2,000$5,000$2,000$1,000$3,000
Net income-$14.62M-$10.57M-$9.60M-$8.90M-$2.87M-$2.78M-$2.23M-$3.34M
EBITDA-$15.70M-$11.70M-$10.75M-$9.98M-$2.92M-$2.84M-$2.31M-$3.38M
EPS (basic)-0.07-0.05-0.05—-0.38-0.58-0.47—
EPS (diluted)-0.07-0.05-0.05—-0.38-0.58-0.47—
Weighted avg. shares (diluted)212.03M211.38M209.66M—7.47M4.80M4.80M—
Balance sheet
Cash & equivalents$113.61M$125.17M$132.63M$133.38M$5.23M$5.42M$7.23M$9.82M
Receivables—$500,000—$0—$0—$0
Current assets$117.47M$127.26M$133.24M$134.22M$6.83M$6.45M$7.89M$10.49M
PP&E, net———$0$0$1,000$2,000$3,000
Total assets$118.55M$127.31M$133.31M$134.34M$6.97M$6.67M$8.19M$10.88M
Current liabilities$5.83M$5.25M$5.62M$4.64M$3.48M$3.97M$2.78M$3.24M
Total liabilities$6.11M$5.57M$5.95M$4.96M$3.76M$4.05M$2.86M$3.39M
Shareholders' equity$112.44M$121.75M$127.36M$129.38M$3.21M$2.62M$5.33M$7.49M
Shares outstanding174.44M173.60M167.42M159.44M9.12M4.80M4.40M2.77M
Cash flow statement
Operating cash flow-$11.76M-$7.60M-$3.89M-$3.14M-$3.55M-$1.82M-$2.33M-$2.38M
Capital expenditure———————$0
Free cash flow———————-$2.38M
Investing cash flow———————$0
Financing cash flow$200,000$147,000$3.13M$131.33M$3.36M$4,000-$258,000$4.16M
Depreciation & amortization$0$0$0$0$1,000$1,000$1,000$0
Stock-based compensation$5.05M$4.78M$4.30M$3.73M$85,000$60,000$69,000$77,000

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.